| **Stable 1: Baseline Characteristics of BRAF V600E and Non-V600E Mutated Patients in Primary and Acquired Groups.** |
| --- |
|  |  | **Primary** |  | **Acquired** |
| ***BRAF* V600E****N=65** | ***BRAF* Non-V600E****N=23** | **P Value** |  | ***BRAF* V600E****N=11** | ***BRAF* Non-V600E****N=4** | **P Value** |
| **Age**Median (Range)  | 66(35-89) | 67(35-89) | 0.482 |  | 59.6(28-78) | 56.8(41-71) | 0.458 |
| **Sex**Male Female | 33(50.8)32(49.2) | 14(60.9)9(39.1) | 0.404 |  | 4(36.4)7(63.6) | 0(0)4(100.0) | 0.159 |
| **ECOG PS**0-1≥2 | 58(89.8)7(10.2) | 21(91.3)2(8.7) | 0.778 |  | 10(90.9)1(9.1) | 2(50.0)2(50.0) | 0.080 |
| **Smoking status**NeverFormer/current Missing | 41(63.1)22(33.8)2(3.1) | 13(56.5)9(39.1)1(4.3) | 0.846 |  | 10(90.9)1(9.1)0(0) | 4(100.0)0(0)0(0) | 0.533 |
| **Histology**AdenocarcinomaOthers | 56(86.2)9(13.8) | 22(95.7)1(4.3) | 0.217 |  | 12(100.0)0(0) | 4(100.0)0(0) | / |
| **Stage**I-IIIAIIIB-IV | 15(23.1)50(76.9) | 8(34.8)15(65.2) | 0.416 |  | 12(100.0)0(0) | 4(100.0)0(0) | / |
| **PD-L1 TPS**<1%1-50%≥50%Not reported | 19(29.2)11(16.0)4(6.2)31(47.7) | 5(21.7)4(17.4)7(30.4)7(30.4) | **0.023** |  | 4(36.4)3(27.3)1(9.1)3(27.3) | 1(25.0)0(0)0(0)3(75.0) | 0.356 |